Pfizer and National Cancer Institute have entered a co-operative research and development (R&D) agreement to develop novel immunotherapy candidates targeting multiple cancers.

Under the terms of the agreement, the two partners will jointly conduct pre-clinical and clinical trials to examine the efficacy of Pfizer’s proprietary investigational immunotherapy agents.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The agreement enables the partners to study the three immunotherapy agents in combination with standard therapies such as chemotherapy, radiation and targeted therapies to treat a range of cancers.

Peakdale Molecular has made an agreement with Metrion Biosciences to create drug discovery programmes for the customers for ion channel targets.

"The agreement enables the two partners to offer integrated drug discovery services."

The agreement enables the two partners to offer integrated drug discovery services to pharmaceutical and biotechnology companies.

See Also:

Selexis and OSE Immunotherapeutics have entered an contract to further develop immunotherapy agents targeting cancer and autoimmune diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the agreement, Selexis’ proprietary SURE technology platform will be utilised to access performance research cell banks (RBCs) and advance the development of OSE Immunotherapuetics’ pre-clinical products.

Pfizer plans to raise gross proceeds of $1.25bn through the public offering of 4.125% notes due 2046.

Skadden, Aprs, Slate, Meagher & Flom is acting as the legal adviser for the offering.

Pfizer plans to use the funds to purchase the tender notes, for general corporate purposes and also to repay its outstanding commercial paper.

Tonghua Golden Horse Pharmaceutical Industry plans for the public offering of bonds. The company expects to raise up to $219m from the offering.

Image: Pfizer Inc plans to raise gross proceeds of $1.25bn through the public offering of 4.125% notes.